Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Plant-strengthening agent enhances natural ability of plants to survive
2015-07-27

Drought, diseases, and fungi. These are factors that farmers have no control over, and they often have to watch despondently as their crops are damaged. In addition, the practice of breeding plants in special and strictly-controlled conditions, has resulted in crops losing the chemical ability to protect themselves in nature.

Researchers in the Department of Soil, Crop, and Climate Sciences at the University of the Free State (UFS) have developed an organic agent that restores this chemical imbalance in plants. It enables the plant to build its own resistance against mild stress factors, and thus ensures increased growth and yield by the plant.

ComCat®, a plant-strengthening agent, is the result of extensive research by the German company, Agraforum AG, together with the UFS. Commercialisation was initially limited to Europe, while research was done at the UFS.

“Plants have become weak because they were grown specially and in isolation. They can’t protect themselves any longer,” says Dr Elmarie van der Watt from the department.

Dr Van der Watt says that, in nature, plants communicate by means of natural chemicals as part of their resistance mechanisms towards various stress conditions. These chemicals enable them to protect themselves against stress conditions, such as diseases and fungi (biotic conditions) or wind and droughts (abiotic conditions).

Most wild plant varieties are usually well-adapted to resist these stress factors. However, monoculture crops have lost this ability to a large extent.

The European researchers extracted these self-protection chemicals from wild plants, and made them available to the UFS for research and development.

“This important survival mechanism became dormant in monoculture crops. ComCat® wakes the plant up and says ‘Hey, you should start protecting yourself’.”

Research over the last few years has shown that the agent, applied mostly as a foliar spray, subsequently leads to better seedlings, as well as to growth, and yields enhancement of various crops. This is good news for the agricultural sector as it does not induce unwanted early vegetative growth that could jeopardise the final yield ? as happened in the past for nitrogen application at an early growth stage.

“The use of synthetic agents, such as fungicides which contain copper, are now banned. Nowadays, options for natural and organic agriculture is being investigated. This product is already widely used in Europe, but because farmers are often swamped by quacks, the South African market is still somewhat sceptical.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept